This post is presented by our media partner Psychedelic News Wire
View the original article here.
Lawmakers in Nevada have approved a bill that would create a psychedelic working group to study hallucinogenics and aid in the development of a therapeutic psychedelic market in the state. Recent efforts by scientists across the country have shown that psychedelics, long considered by federal law as controlled drugs with zero medical application, may be able to alleviate a wide variety of mental health disorders.
Researchers have found that when paired with talk therapy, even a single dose of a psychedelic such as psilocybin can offer patients sustained and long-term relief against the symptoms of conditions such as treatment-resistant depression and post-traumatic stress disorder (PTSD). Nevada now joins the growing number of regions that have either passed some kind of psychedelics regulations or are considering joining the young but swiftly growing industry.
The state legislature passed the psychedelics bill in a unanimous vote and sent it to the governor’s desk for his consideration and signature. Introduced by Senator Rochelle Nguyen, the measure would have originally expanded the scope of psychedelic research in Nevada as well as legalized psilocybin, the main psychoactive agent in magic mushrooms.
However, the measure was scaled back by the Senate to focus solely on creating a psychedelic medicines working group charged with investigating the therapeutic, medicinal and wellness potential of entheogens. Entheogens include psychedelics such as psilocybin, ayahuasca and peyote, which are derived from naturally occurring fungi and plants.
Nguyen noted earlier that her bill would most likely be amended and said that she did not mind any changes; she simply wanted to get the legislature talking about psychedelic reform.
If the bill is signed into law, it will result in the formation of a 15-member working group under the auspices of the Nevada Department of Health and Human Services (HHS). The members would include the director of HSS, the state attorney general, the president of the Nevada Board of Pharmacology, and the director of veteran services.
The working group will be in charge of investigating the therapeutic potential of hallucinogenics, including but not limited to psilocin and psilocybin, in overall wellness and against mental disorders such as substance use disorder, major depressive disorder and PTSD.
Additionally, the working group would be tasked with analyzing local, state and federal laws on the medical use of psychedelics and coming up with an actionable plan for how Nevada can allow access to safe, affordable and effective entheogens. The group would also have to compile its findings into a report and submit that report to the state legislature by Dec. 31, 2024.
The working group created in Nevada could benefit from some of the scientific data that enterprises such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) have documented regarding the therapeutic potential of a number of hallucinogens.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
This post was originally published by our media partner here.
